Emerging Nanotechnology in Preclinical Pancreatic Cancer Immunotherapy: Driving Towards Clinical Applications
Xuan Pan,Ting Han,Zixuan Zhao,Xiaoming Wang,Xiaosan Fang
DOI: https://doi.org/10.2147/ijn.s466459
IF: 7.033
2024-07-03
International Journal of Nanomedicine
Abstract:Xuan Pan, 1, &ast Ting Han, 2, &ast Zixuan Zhao, 3, 4 Xiaoming Wang, 1 Xiaosan Fang 1 1 Department of Hepato-Biliary-Pancreatic Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People's Republic of China; 2 Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People's Republic of China; 3 The Translational Research Institute for Neurological Disorders of Department of Neurosurgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241000, People's Republic of China; 4 The Institute of Brain Science, Wannan Medical College, Wuhu, 241000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaosan Fang; Xiaoming Wang, Department of Hepato-Biliary-Pancreatic Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), 2 West Zheshan Road, Wuhu, 241002, People's Republic of China, Tel +86-0553-5739219, Email ; The high malignant degree and poor prognosis of pancreatic cancer (PC) pose severe challenges to the basic research and clinical translation of next-generation therapies. The rise of immunotherapy has improved the treatment of a variety of solid tumors, while the application in PC is highly restricted by the challenge of immunosuppressive tumor microenvironment. The latest progress of nanotechnology as drug delivery platform and immune adjuvant has improved drug delivery in a variety of disease backgrounds and enhanced tumor therapy based on immunotherapy. Based on the immune loop of PC and the status quo of clinical immunotherapy of tumors, this article discussed and critically analyzed the key transformation difficulties of immunotherapy adaptation to the treatment of PC, and then proposed the rational design strategies of new nanocarriers for drug delivery and immune regulation, especially the design of combined immunotherapy. This review also put forward prospective views on future research directions, so as to provide information for the new means of clinical treatment of PC combined with the next generation of nanotechnology and immunotherapy. Keywords: pancreatic cancer, immunotherapy, nanomedicine, immunosuppressive tumor microenvironment regulation, combined drug delivery strategy Graphical Pancreatic cancer (PC) is a highly lethal malignant tumor with the characteristics of insidious onset, rapid progression, and poor prognosis. According to the World Health Organization (WHO) classification, PC has been divided into epithelial and non-epithelial origins based on tissue origin, with ductal adenocarcinoma originating from adenocarcinoma accounting for 80–90% of all PC types. Statistics show that PC mortality still ranks fourth among tumor-related causes of death, while the overall five-year survival rate is only about 7% and the mortality-to-incidence ratio (M/I) is approximately 0.94, ranking first among all common tumors. 1 The extremely malignant nature and poor prognosis reflected thus pose a more severe challenge to the basic transformation and clinical research of PC. Surgery is the only potential cure for PC but over 80% of patients are already in locally advanced or metastatic PC at the time of diagnosis, missing the opportunity for surgical resection and cure. Therefore, the treatment of advanced PC mainly relies on drug therapy. For a long time, the drug options for first-line treatment of PC have been very limited, with gemcitabine-based treatment regimens and the FOLFIRINOX (a four-drug combination chemotherapy regimen of fluorouracil, calcium folinate, irinotecan and oxaliplatin) regimen and its modified regimens remaining the main treatment options. 2–4 However, with the advancement of treatment, increasing drug resistance and cumulative toxicity, patients will soon face a dilemma where there are no drugs available. 5 The development of immunotherapies to activate the immune system to effectively eradicate tumor cells has already changed the outlook for patients with advanced solid tumors. Mainstream of tumor immunotherapy includes immune checkpoint blockade (ICB) represented by PD-1/PD-L1 inhibitors, tumor vaccines that induce immune responses by presenting specific antigens, and CAR-T therapy that modifies T cells for specific recognition and killing. 6–8 However, only 1% of PC patients with microsatellite instability may benefit from a single dose of immunotherapy because of the unique resistance of PC to immunotherapy. The failure is mainly blamed on the -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology